RxDoctor Payments Data

Natalia Albright

Psychiatric/Mental Health · Forest Hill, TXNPI 1023446457

Payments from drug & device makers

$1,168in general payments, 2019–2025

Across 12 payments — averaging $97.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$360
  • Eisai Inc.$121
  • AbbVie$121
  • E.r. Squibb & Sons, L.L.C.$117
  • Alkermes, Inc.$114
  • Teva Pharmaceuticals USA, Inc.$102
  • plus $235 from 3 others

What the payments were for

  • Food & beverage$1,168100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,168 in reported general payments places this provider in the 65th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$9,630
Medicare patients
28
Services billed
248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate34$294,902
AristadaAripiprazole Lauroxil82$285,875
Invega SustennaPaliperidone Palmitate38$97,617
IngrezzaValbenazine Tosylate12$91,341
VraylarCariprazine Hcl26$59,413
Risperdal ConstaRisperidone Microspheres26$32,579
FanaptIloperidone14$24,401
Lurasidone Hcl34$20,385
Asenapine Maleate11$3,025
Haloperidol Decanoate42$2,390
Oxcarbazepine35$2,248
Paliperidone ErPaliperidone14$2,217
Fluoxetine Hcl65$1,913
Aripiprazole21$1,613
Duloxetine Hcl41$1,442

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna, Risperdal Consta$68$425,09898 claims
Alkermes, Inc.Aristada$114$285,87582 claims
Neurocrine Biosciences, Inc.Ingrezza$81$91,34112 claims
AbbVieVraylar$121$59,41326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Forest Hill

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →